Agios Pharmaceuticals (AGIO) Cost of Revenue (2018 - 2025)
Historic Cost of Revenue for Agios Pharmaceuticals (AGIO) over the last 7 years, with Q3 2025 value amounting to $1.7 million.
- Agios Pharmaceuticals' Cost of Revenue rose 11443.17% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year increase of 6402.18%. This contributed to the annual value of $4.2 million for FY2024, which is 4456.79% up from last year.
- Agios Pharmaceuticals' Cost of Revenue amounted to $1.7 million in Q3 2025, which was up 11443.17% from $1.7 million recorded in Q2 2025.
- In the past 5 years, Agios Pharmaceuticals' Cost of Revenue ranged from a high of $1.7 million in Q2 2025 and a low of $339000.0 during Q1 2022
- Its 4-year average for Cost of Revenue is $881066.7, with a median of $633000.0 in 2023.
- Per our database at Business Quant, Agios Pharmaceuticals' Cost of Revenue skyrocketed by 15471.26% in 2023 and then skyrocketed by 1317.69% in 2024.
- Over the past 4 years, Agios Pharmaceuticals' Cost of Revenue (Quarter) stood at $413000.0 in 2022, then skyrocketed by 41.89% to $586000.0 in 2023, then skyrocketed by 115.02% to $1.3 million in 2024, then skyrocketed by 33.25% to $1.7 million in 2025.
- Its Cost of Revenue stands at $1.7 million for Q3 2025, versus $1.7 million for Q2 2025 and $1.1 million for Q1 2025.